{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Gwynette MF"],"funding":["NIDA NIH HHS"],"pagination":["346-351"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC10150802"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["13(3)"],"pubmed_abstract":["Patients with autism spectrum disorder (ASD) are at high risk for comorbid major depressive disorder (MDD), which can severely impair functioning and quality of life. Repetitive transcranial magnetic stimulation (rTMS) is a noninvasive brain stimulation technique, which is Food and Drug Administration (FDA) cleared for the treatment of MDD in adults. Despite demonstrated efficacy in the treatment of depression, there are limited data on the use of rTMS in patients with ASD and comorbid MDD. We hypothesized that a standard rTMS protocol for MDD would reduce depressive symptoms for adults with ASD and MDD. Secondarily, we investigated whether this treatment would also reduce core ASD symptoms. Participants of 18-65 years old with ASD and MDD without any medication changes in the last month w"],"journal":["Autism research : official journal of the International Society for Autism Research"],"pubmed_title":["Treatment of Adults with Autism and Major Depressive Disorder Using Transcranial Magnetic Stimulation: An Open Label Pilot Study."],"pmcid":["PMC10150802"],"funding_grant_id":["K23 DA043628"],"pubmed_authors":["George MS","Lohnes L","Alsarraf H","Joseph JE","Gwynette MF","Wiley MG","Summers PM","Lowe DW","Henneberry EA","Sahlem GL","Russo SB"],"additional_accession":[]},"is_claimable":false,"name":"Treatment of Adults with Autism and Major Depressive Disorder Using Transcranial Magnetic Stimulation: An Open Label Pilot Study.","description":"Patients with autism spectrum disorder (ASD) are at high risk for comorbid major depressive disorder (MDD), which can severely impair functioning and quality of life. Repetitive transcranial magnetic stimulation (rTMS) is a noninvasive brain stimulation technique, which is Food and Drug Administration (FDA) cleared for the treatment of MDD in adults. Despite demonstrated efficacy in the treatment of depression, there are limited data on the use of rTMS in patients with ASD and comorbid MDD. We hypothesized that a standard rTMS protocol for MDD would reduce depressive symptoms for adults with ASD and MDD. Secondarily, we investigated whether this treatment would also reduce core ASD symptoms. Participants of 18-65 years old with ASD and MDD without any medication changes in the last month w","dates":{"release":"2020-01-01T00:00:00Z","publication":"2020 Mar","modification":"2025-04-22T02:34:26.351Z","creation":"2025-04-05T20:23:29.002Z"},"accession":"S-EPMC10150802","cross_references":{"pubmed":["31944611"],"doi":["10.1002/aur.2266"]}}